High versus low radioiodine activity in patients with differentiated thyroid cancer: A meta-analysis

Acta Oncologica

Volumn 52, Issue 6, 2013, Pages 1055-1061

  Valachis, Antonis ^a,b   Nearchou, Andreas ^a  

^a Mälarsjukhuset ^*  (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE;

CANCER PATIENT; DIFFERENTIATED THYROID CANCER; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; NAUSEA; NECK PAIN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SALIVARY GLAND DISEASE; SIDE EFFECT; SYSTEMATIC REVIEW; THYROIDECTOMY; CANCER SURGERY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FOLLOW UP; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; MANTEL HAENSZEL TEST; QUALITY CONTROL; SENSITIVITY ANALYSIS; SUBTOTAL THYROIDECTOMY; THERAPY EFFECT; THYROGLOBULIN BLOOD LEVEL; TREATMENT OUTCOME;

HUMANS; IODINE RADIOISOTOPES; RADIATION DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THYROID NEOPLASMS;

EID: 84880294020     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.742959     Document Type: Review

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Liu S, Semenciw R, Ugnat AM, Mao Y. I ncreasing thyroid cancer incidence in Canada, 1970-1996: Time trends and age-period-cohort effects. Br J Cancer 2001; 85: 1335-9.
3. Chen AY, Jemal A, Ward E M. I ncreasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009; 115: 3801-7.
4. Kilfoy BA, Zheng T, Holford T R, Han X, Ward MH, Sjodin A, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 2009; 20: 525-31.
5. How J, Tabah R. E xplaining the increasing incidence of differentiated thyroid cancer. CMAJ 2007; 177: 1383-4.
6. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89: 3668-76.
7. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008; 37: 457-80.
8. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit J WA, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
9. Tuttle R M, Ball D W, Byrd D, Dilawari R A, Doherty GM, Duh QY, et al National Comprehensive Cancer Network. Thyroid carcinoma. J Natl Compr Canc Netw 2010; 8: 1228-74.
10. Pacini F, Castagna MG, Brilli L, Pentheroudakis G; ESMO Guidelines Working Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): V214-9.
11. Reiners C, Farahati J. I 131 therapy of thyroid cancer patient. Q J Nucl Med 1999; 43: 324-35.
12. Creutzig H. H igh or low dose radioiodine ablation of thyroid remnants? Eur J Nucl Med 1987; 12: 500-2.
13. Johansen K, Woodhouse N JY, Odugbesan O. C omparison of 1073 MBq and 3700 MBq iodine-131 in post-operative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991; 32: 252-4.
14. Bal C S, Padhy AK, Jana S, Pant G S, Basu AK. P rospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996; 77: 2574-80.
15. Gawkowska-Suwinska M, Turska M, Roskosz J, Puch Z, Jurecka-Tuleja B, Handkiewicz-Junak D, et al. Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer. Wiad Lek 2001; 54(Suppl 1): 278-88.
16. Bal C S, Kumar A, Pant G S. R adioiodine dose for remnant ablation in differentiated thyroid carcinoma: A randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004; 89: 1666-73.
17. Mäe npää HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: A randomized study. PLoS One 2008; 3: E1885.
18. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 2007; 92: 28-38.
19. Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani K A, Saghari M, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: A large randomized clinical trial. Nucl Med Commun 2012; 33: 275-82.
20. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012; 366: 1674-85.
21. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al; Tumeurs de la Thyro ï de Refractaires Network for the Essai Stimulation Ablation Equivalence Trial. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012; 366: 1663-73.
22. Higgins J P, Altman D G, Gøt zsche P C, J üni P, Moher D, Oxman AD, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: D5928.
23. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Le SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214.
24. Iyer NG, Morris LGT, Tuttle RM, Shaha A R, Ganly I. R ising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011; 117: 4439-46.
25. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: A systematic review and meta-analysis. Thyroid 2009; 19: 451-7.
26. Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieff éS, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab 2012; 97: 1526-35.
27. Kim E Y, Kim TY, Kim W G, Yim J H, Han J M, Ryu J S, et a l. Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma. Nucl Med Commun 2011; 32: 954-9.
28. Mallick U, Harmer C, Hackshaw A, Moss L. I odine or Not (IoN) for low-risk differentiated thyroid cancer; the next UK National Cancer Research Network randomized trial following HiLo. Clin Oncol (R Coll Radiol) 2012; 24: 159-61.
29. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, et al. A comparison of shortterm changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006; 91: 878-84.
30. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 2010; 20: 173-9.
31. Alexander EK, Larsen PR. R adioiodine for thyroid cancer-is less more? N Engl J Med 2012; 366: 1732-3.
32. Jones AP, Riley RD, Williamson PR, Whitehead A. M etaanalysis of individual patient data versus aggregate data from longitudinal clinical trials. Clin Trials 2009; 6: 16-27.